Study objective–The aim of the study was to measure plasma neuropeptide Y, which is
related to sympathetic nerve stimulation, in patients admitted to a coronary care unit and to …

Plasma neuropeptide Y-like immunoreactivity (NPY-LI) is elevated in patients with acute
myocardial ischaemia and congestive heart failure (CHF) owing to increased activity of the …

Abstract Aims Neuropeptide Y (NPY) is the most abundant neuropeptide found in the heart
and is released alongside norepinephrine following prolonged sympathetic activation, a …

Abstract purpose: Our objectives were to assess whether plasma neuropeptide Y (NPY)
levels are elevated in patients with congestive heart failure (CHF) and whether or not NPY …

OBJECTIVE--To measure plasma concentrations of noradrenaline and neuropeptide Y-like
immunoreactivity in relation to cardiac function in patients with congestive heart failure …

Neuropeptide Y coexists with norepinephrine in sympathetic nerves and is coreleased into
the circulation on sympathetic activation. Little is known about the regional release of …

Objectives The co-transmitter neuropeptide Y (NPY) is released during high levels of
sympathetic stimulation and is a potent vasoconstrictor. We defined the release profile of …

Background The sympathetic cotransmitter, neuropeptide Y (NPY), is released into the
coronary sinus during ST‐segment–elevation myocardial infarction and can constrict the …

Neuropeptide Y is one of the most abundant neurotransmitters in the myocardium, and is
known to influence cardiovascular remodeling. We hypothesized that diabetic neuropathy …

Chronic renal insufficiency is a situation characterized by high plasma concentration of
neuropeptide Y (NPY). Because this neuropeptide interferes with cardiovascular (CV) …